Cita APA (7a ed.)
Zhu, G., Zeng, L., Yang, L., Zhang, X., Tang, J., Pan, Y., . . . Wu, T. (2024). Is atezolizumab plus bevacizumab as first-line therapy for unresectable hepatocellular carcinoma superior to lenvatinib? a systematic review and meta‑analysis. European Journal of Clinical Pharmacology, 80(10), 1425-1435.
Cita Chicago Style (17a ed.)
Zhu, Gang, Longfei Zeng, Liu Yang, Xin Zhang, Jinquan Tang, Yong Pan, Bo Li, Mengchen Chen, y Tao Wu. "Is Atezolizumab Plus Bevacizumab as First-line Therapy for Unresectable Hepatocellular Carcinoma Superior to Lenvatinib? a Systematic Review and Meta‑analysis." European Journal of Clinical Pharmacology 80, no. 10 (2024): 1425-1435.
Cita MLA (9a ed.)
Zhu, Gang, et al. "Is Atezolizumab Plus Bevacizumab as First-line Therapy for Unresectable Hepatocellular Carcinoma Superior to Lenvatinib? a Systematic Review and Meta‑analysis." European Journal of Clinical Pharmacology, vol. 80, no. 10, 2024, pp. 1425-1435.
Precaución: Estas citas no son 100% exactas.